Onconova Therapeutics to Provide Corporate Update and First Quarter 2020 Earnings on May 14, 2020
May 07 2020 - 8:00AM
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage
biopharmaceutical company focused on discovering and developing
novel products to treat cancer, with an initial focus on
myelodysplastic syndromes (MDS), today announced that the Company
will release its first quarter financial results on Thursday,
May 14, 2020, after the market closes. Management will host a
conference call and live webcast at 4:30 p.m. ET on the same day to
discuss these results and provide an update on its pipeline
programs.
Interested parties who wish to participate in
the conference call may do so by dialing (855) 428-5741 for
domestic and (210) 229-8823 for international callers and using
conference ID 3488818. To facilitate an on-time conference call
start, Onconova recommends that participants dial in 15 minutes
before the 4:30 p.m. ET start time.
Those interested in listening to the conference
call live via the internet may do so by visiting the investors’
page of the company's website at www.onconova.com and
clicking on the webcast link.
A webcast replay will be available on the
Onconova website for 90 days following the call by visiting the
investor page of the company's website at www.onconova.com
About Onconova Therapeutics,
Inc.
Onconova Therapeutics, Inc. is a Phase 3-stage
biopharmaceutical company focused on discovering and developing
novel drugs to treat cancer, with an initial focus on
myelodysplastic syndromes (MDS). Onconova has a pipeline of
proprietary targeted agents designed to work against specific
cellular pathways that are important in cancer cells. Advanced
clinical trials with the Company’s lead compound, rigosertib, are
aimed at what the Company believes are unmet medical needs of
patients with MDS. Onconova has conducted trials with two other
research compounds and has a pre-clinical program with a CDK4/6 and
ARK5 inhibitor, ON 123300.
For more information, please visit
https://www.onconova.com/.
Forward-Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995, and involve risks and uncertainties.
These statements relate to Onconova expectations regarding the
INSPIRE Trial and Onconova’s other development plans. Onconova has
attempted to identify forward-looking statements by terminology
including "believes," "estimates," "anticipates," "expects,"
"plans," "intends," "may," "could," "might," "will," "should,"
"approximately" or other words that convey uncertainty of future
events or outcomes. Although Onconova believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, including Onconova's ability to continue as a going
concern, maintain its Nasdaq listing, the need for additional
financing, the success and timing of Onconova's clinical trials and
regulatory approval of protocols, our collaborations including the
effective termination of the HanX license and securities purchase
agreements and plans for partnering certain territories, and those
discussed under the heading "Risk Factors" in Onconova's most
recent Annual Report on Form 10-K and quarterly reports on Form
10-Q. Any forward-looking statements contained in this release
speak only as of its date. Onconova undertakes no obligation to
update any forward-looking statements contained in this release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
Press release contact
information
Company Contact:Avi
OlerOnconova Therapeutics, Inc. 267-759-3680ir@onconova.us
http://www.onconova.com/contact/
MediaDavid Schull, Russo Partners
LLC: (212) 845-4271Nic Johnson, Russo Partners LLC: (212)
845-4242
InvestorsJan Medina, CFA, Russo Partners LLC:
(646) 942-5632
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Apr 2023 to Apr 2024